Filing Overview
Motion Acquisition Corp. filed this Form 8-K on July 20, 2021 under Item 7.01 (Regulation FD Disclosure). The filing concerns its proposed business combination with Ambulnz, Inc., doing business as DocGo. The parties announced preliminary unaudited results for DocGo’s second quarter ended June 30, 2021 and furnished an updated investor presentation.
Financial Metrics
The filing text provided does not include the preliminary second-quarter revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics. Those details appear to have been included in Exhibit 99.1, which is referenced but not reproduced in the supplied text.
The filing states that certain financial information may be presented on a non-GAAP basis and may not conform to SEC Regulation S-X or U.S. GAAP. The information is expected to be adjusted and presented differently in the registration statement.
Material Changes and Transaction Status
- Motion Acquisition Corp. had entered into a merger agreement with DocGo and its wholly owned merger subsidiary.
- The July 20 announcement provided selected preliminary unaudited results for the quarter ended June 30, 2021; the filing text does not provide comparable prior-period results or quantify changes.
- An updated investor presentation was furnished as Exhibit 99.2.
- Motion had filed a preliminary Form S-4 registration statement containing a proxy statement/prospectus for stockholder approval of the proposed transaction.
Outlook, Risks, and Unusual Items
- The filing contains forward-looking statements regarding projected financial and performance metrics, market opportunity, the proposed merger, and DocGo’s expansion plans. These projections are expressly described as illustrative and not guarantees of future performance.
- Completion of the merger remained subject to conditions including Motion stockholder approval, potential organizational-document amendments extending the deadline for completing the initial business combination, regulatory approvals, and other closing conditions.
- Identified risks include termination of the merger agreement, legal proceedings, transaction costs, failure to realize anticipated benefits, uncertainty in projected financial information, competition, expansion execution, and the effects of the COVID-19 pandemic.
- The filing was furnished rather than filed for Section 18 liability purposes, except where specifically incorporated by reference.
Investor Verification Items
- Review Exhibit 99.1 for DocGo’s actual second-quarter revenue, profitability, cash flow, margins, balance-sheet data, and year-over-year comparisons.
- Review Exhibit 99.2 and the Form S-4 for transaction terms, projected financial information, capitalization, dilution, and valuation assumptions.
- Confirm the status of required stockholder, regulatory, and other merger approvals and the applicable completion deadline.
- Assess the reconciliation and appropriate use of the company’s non-GAAP financial measures.
- Review the definitive proxy statement/prospectus for risk factors, transaction-related expenses, management interests, and any changes to the preliminary disclosures.